nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CHEK2—ovarian cancer	0.306	0.657	CbGaD
Gefitinib—EGFR—ovarian cancer	0.122	0.263	CbGaD
Gefitinib—EGFR—Docetaxel—ovarian cancer	0.0759	0.294	CbGbCtD
Gefitinib—ABCB1—ovarian cancer	0.0372	0.0799	CbGaD
Gefitinib—ABCG2—Topotecan—ovarian cancer	0.035	0.136	CbGbCtD
Gefitinib—ABCG2—Paclitaxel—ovarian cancer	0.0173	0.0672	CbGbCtD
Gefitinib—ABCG2—Carboplatin—ovarian cancer	0.0163	0.0632	CbGbCtD
Gefitinib—ABCB1—Topotecan—ovarian cancer	0.0126	0.0489	CbGbCtD
Gefitinib—ABCG2—Docetaxel—ovarian cancer	0.0125	0.0486	CbGbCtD
Gefitinib—CYP3A5—Paclitaxel—ovarian cancer	0.0096	0.0372	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—ovarian cancer	0.00934	0.0362	CbGbCtD
Gefitinib—ABCB1—Vinorelbine—ovarian cancer	0.0089	0.0345	CbGbCtD
Gefitinib—CYP2D6—Vinorelbine—ovarian cancer	0.00838	0.0325	CbGbCtD
Gefitinib—CYP3A4—Topotecan—ovarian cancer	0.00757	0.0293	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—ovarian cancer	0.00694	0.0269	CbGbCtD
Gefitinib—CYP2C9—Paclitaxel—ovarian cancer	0.00644	0.025	CbGbCtD
Gefitinib—ABCB1—Paclitaxel—ovarian cancer	0.00625	0.0242	CbGbCtD
Gefitinib—CYP3A4—Vinorelbine—ovarian cancer	0.00533	0.0207	CbGbCtD
Gefitinib—ABCB1—Docetaxel—ovarian cancer	0.00452	0.0175	CbGbCtD
Gefitinib—CYP3A4—Paclitaxel—ovarian cancer	0.00375	0.0145	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—ovarian cancer	0.00337	0.0131	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—ovarian cancer	0.00317	0.0123	CbGbCtD
Gefitinib—CYP3A4—Docetaxel—ovarian cancer	0.00271	0.0105	CbGbCtD
Gefitinib—CYP3A4—Doxorubicin—ovarian cancer	0.00202	0.00782	CbGbCtD
Gefitinib—CHEK2—myometrium—ovarian cancer	0.00149	0.0225	CbGeAlD
Gefitinib—SBK1—endometrium—ovarian cancer	0.0012	0.0182	CbGeAlD
Gefitinib—Lapatinib—ERBB2—ovarian cancer	0.00115	0.237	CrCbGaD
Gefitinib—CHEK2—decidua—ovarian cancer	0.0011	0.0167	CbGeAlD
Gefitinib—HIPK4—gonad—ovarian cancer	0.0011	0.0167	CbGeAlD
Gefitinib—HIPK4—female reproductive system—ovarian cancer	0.000984	0.0149	CbGeAlD
Gefitinib—CSNK1E—myometrium—ovarian cancer	0.000943	0.0143	CbGeAlD
Gefitinib—IRAK4—myometrium—ovarian cancer	0.000928	0.0141	CbGeAlD
Gefitinib—ERBB3—embryo—ovarian cancer	0.000875	0.0133	CbGeAlD
Gefitinib—EPHA6—gonad—ovarian cancer	0.000871	0.0132	CbGeAlD
Gefitinib—MKNK2—myometrium—ovarian cancer	0.000865	0.0131	CbGeAlD
Gefitinib—MKNK1—myometrium—ovarian cancer	0.000854	0.0129	CbGeAlD
Gefitinib—CHEK2—Docetaxel—Paclitaxel—ovarian cancer	0.000838	0.287	CbGdCrCtD
Gefitinib—CHEK2—bone marrow—ovarian cancer	0.000819	0.0124	CbGeAlD
Gefitinib—Afatinib—ERBB2—ovarian cancer	0.000816	0.168	CrCbGaD
Gefitinib—SBK1—testis—ovarian cancer	0.000804	0.0122	CbGeAlD
Gefitinib—HIPK4—testis—ovarian cancer	0.000794	0.012	CbGeAlD
Gefitinib—CHEK2—female gonad—ovarian cancer	0.000789	0.012	CbGeAlD
Gefitinib—CHEK2—vagina—ovarian cancer	0.000785	0.0119	CbGeAlD
Gefitinib—EPHA6—female reproductive system—ovarian cancer	0.000778	0.0118	CbGeAlD
Gefitinib—EGFR—uterine cervix—ovarian cancer	0.000763	0.0116	CbGeAlD
Gefitinib—CSNK1E—uterine cervix—ovarian cancer	0.000734	0.0111	CbGeAlD
Gefitinib—IRAK4—uterine cervix—ovarian cancer	0.000723	0.0109	CbGeAlD
Gefitinib—ERBB3—epithelium—ovarian cancer	0.000714	0.0108	CbGeAlD
Gefitinib—ERBB3—uterine cervix—ovarian cancer	0.000708	0.0107	CbGeAlD
Gefitinib—MAP3K19—female reproductive system—ovarian cancer	0.000707	0.0107	CbGeAlD
Gefitinib—STK10—myometrium—ovarian cancer	0.000704	0.0107	CbGeAlD
Gefitinib—CHEK2—testis—ovarian cancer	0.0007	0.0106	CbGeAlD
Gefitinib—CSNK1E—decidua—ovarian cancer	0.000699	0.0106	CbGeAlD
Gefitinib—IRAK4—decidua—ovarian cancer	0.000688	0.0104	CbGeAlD
Gefitinib—MKNK2—epithelium—ovarian cancer	0.000679	0.0103	CbGeAlD
Gefitinib—MKNK2—uterine cervix—ovarian cancer	0.000673	0.0102	CbGeAlD
Gefitinib—IRAK1—uterine cervix—ovarian cancer	0.000673	0.0102	CbGeAlD
Gefitinib—MKNK1—uterine cervix—ovarian cancer	0.000665	0.0101	CbGeAlD
Gefitinib—CSNK1E—endometrium—ovarian cancer	0.000664	0.0101	CbGeAlD
Gefitinib—IRAK4—endometrium—ovarian cancer	0.000653	0.0099	CbGeAlD
Gefitinib—MKNK2—decidua—ovarian cancer	0.000642	0.00972	CbGeAlD
Gefitinib—IRAK1—decidua—ovarian cancer	0.000642	0.00972	CbGeAlD
Gefitinib—EGFR—uterus—ovarian cancer	0.000636	0.00963	CbGeAlD
Gefitinib—MKNK1—decidua—ovarian cancer	0.000634	0.00959	CbGeAlD
Gefitinib—MAP2K5—myometrium—ovarian cancer	0.000628	0.00952	CbGeAlD
Gefitinib—EPHA6—testis—ovarian cancer	0.000628	0.00951	CbGeAlD
Gefitinib—CSNK1E—uterus—ovarian cancer	0.000612	0.00926	CbGeAlD
Gefitinib—MKNK2—endometrium—ovarian cancer	0.000609	0.00922	CbGeAlD
Gefitinib—MKNK1—endometrium—ovarian cancer	0.000601	0.00911	CbGeAlD
Gefitinib—ERBB3—uterus—ovarian cancer	0.00059	0.00894	CbGeAlD
Gefitinib—SBK1—lymph node—ovarian cancer	0.000582	0.00882	CbGeAlD
Gefitinib—MAP3K19—testis—ovarian cancer	0.000571	0.00864	CbGeAlD
Gefitinib—MKNK2—gonad—ovarian cancer	0.000565	0.00856	CbGeAlD
Gefitinib—MKNK2—uterus—ovarian cancer	0.000561	0.0085	CbGeAlD
Gefitinib—MKNK1—gonad—ovarian cancer	0.000558	0.00845	CbGeAlD
Gefitinib—CSNK1E—female reproductive system—ovarian cancer	0.00055	0.00833	CbGeAlD
Gefitinib—STK10—uterine cervix—ovarian cancer	0.000548	0.00829	CbGeAlD
Gefitinib—Lapatinib—EGFR—ovarian cancer	0.000544	0.112	CrCbGaD
Gefitinib—CHEK2—Vindesine—Vinorelbine—ovarian cancer	0.000533	0.182	CbGdCrCtD
Gefitinib—ERBB3—female reproductive system—ovarian cancer	0.000531	0.00804	CbGeAlD
Gefitinib—STK10—decidua—ovarian cancer	0.000522	0.0079	CbGeAlD
Gefitinib—EGFR—female gonad—ovarian cancer	0.00052	0.00788	CbGeAlD
Gefitinib—IRAK4—bone marrow—ovarian cancer	0.000511	0.00774	CbGeAlD
Gefitinib—CHEK2—lymph node—ovarian cancer	0.000507	0.00768	CbGeAlD
Gefitinib—MKNK2—female reproductive system—ovarian cancer	0.000505	0.00764	CbGeAlD
Gefitinib—IRAK1—female reproductive system—ovarian cancer	0.000505	0.00764	CbGeAlD
Gefitinib—CSNK1E—female gonad—ovarian cancer	0.0005	0.00758	CbGeAlD
Gefitinib—MKNK1—female reproductive system—ovarian cancer	0.000498	0.00754	CbGeAlD
Gefitinib—CSNK1E—vagina—ovarian cancer	0.000497	0.00753	CbGeAlD
Gefitinib—IRAK4—female gonad—ovarian cancer	0.000493	0.00746	CbGeAlD
Gefitinib—IRAK4—vagina—ovarian cancer	0.00049	0.00741	CbGeAlD
Gefitinib—MAP2K5—uterine cervix—ovarian cancer	0.000489	0.00741	CbGeAlD
Gefitinib—ERBB3—female gonad—ovarian cancer	0.000483	0.00731	CbGeAlD
Gefitinib—MKNK2—bone marrow—ovarian cancer	0.000476	0.00721	CbGeAlD
Gefitinib—IRAK1—bone marrow—ovarian cancer	0.000476	0.00721	CbGeAlD
Gefitinib—MKNK1—bone marrow—ovarian cancer	0.00047	0.00712	CbGeAlD
Gefitinib—MAP2K5—decidua—ovarian cancer	0.000466	0.00706	CbGeAlD
Gefitinib—EGFR—testis—ovarian cancer	0.000462	0.00699	CbGeAlD
Gefitinib—STK10—gonad—ovarian cancer	0.000459	0.00696	CbGeAlD
Gefitinib—MKNK2—female gonad—ovarian cancer	0.000459	0.00695	CbGeAlD
Gefitinib—IRAK1—female gonad—ovarian cancer	0.000459	0.00695	CbGeAlD
Gefitinib—STK10—uterus—ovarian cancer	0.000456	0.00691	CbGeAlD
Gefitinib—MKNK2—vagina—ovarian cancer	0.000456	0.00691	CbGeAlD
Gefitinib—MKNK1—female gonad—ovarian cancer	0.000453	0.00687	CbGeAlD
Gefitinib—MKNK1—vagina—ovarian cancer	0.000451	0.00682	CbGeAlD
Gefitinib—CSNK1E—testis—ovarian cancer	0.000444	0.00672	CbGeAlD
Gefitinib—MAP2K5—endometrium—ovarian cancer	0.000442	0.0067	CbGeAlD
Gefitinib—IRAK4—testis—ovarian cancer	0.000437	0.00662	CbGeAlD
Gefitinib—ERBB3—testis—ovarian cancer	0.000428	0.00649	CbGeAlD
Gefitinib—Bosutinib—CHEK2—ovarian cancer	0.00042	0.0866	CrCbGaD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—ovarian cancer	0.000418	0.143	CbGdCrCtD
Gefitinib—STK10—female reproductive system—ovarian cancer	0.00041	0.00621	CbGeAlD
Gefitinib—MKNK2—testis—ovarian cancer	0.000407	0.00617	CbGeAlD
Gefitinib—IRAK1—testis—ovarian cancer	0.000407	0.00617	CbGeAlD
Gefitinib—MKNK1—testis—ovarian cancer	0.000402	0.00609	CbGeAlD
Gefitinib—STK10—bone marrow—ovarian cancer	0.000387	0.00587	CbGeAlD
Gefitinib—Afatinib—EGFR—ovarian cancer	0.000386	0.0795	CrCbGaD
Gefitinib—STK10—female gonad—ovarian cancer	0.000373	0.00565	CbGeAlD
Gefitinib—STK10—vagina—ovarian cancer	0.000371	0.00562	CbGeAlD
Gefitinib—MAP2K5—female reproductive system—ovarian cancer	0.000366	0.00555	CbGeAlD
Gefitinib—ORM1—endometrium—ovarian cancer	0.000359	0.00544	CbGeAlD
Gefitinib—ERBB3—Vinblastine—Vinorelbine—ovarian cancer	0.000342	0.117	CbGdCrCtD
Gefitinib—EGFR—lymph node—ovarian cancer	0.000335	0.00507	CbGeAlD
Gefitinib—MAP2K5—female gonad—ovarian cancer	0.000333	0.00505	CbGeAlD
Gefitinib—MAP2K5—vagina—ovarian cancer	0.000331	0.00502	CbGeAlD
Gefitinib—STK10—testis—ovarian cancer	0.000331	0.00501	CbGeAlD
Gefitinib—CSNK1E—lymph node—ovarian cancer	0.000322	0.00487	CbGeAlD
Gefitinib—IRAK4—lymph node—ovarian cancer	0.000317	0.0048	CbGeAlD
Gefitinib—ERBB3—lymph node—ovarian cancer	0.00031	0.0047	CbGeAlD
Gefitinib—ABCG2—myometrium—ovarian cancer	0.000306	0.00463	CbGeAlD
Gefitinib—ORM1—female reproductive system—ovarian cancer	0.000297	0.0045	CbGeAlD
Gefitinib—MAP2K5—testis—ovarian cancer	0.000296	0.00448	CbGeAlD
Gefitinib—MKNK2—lymph node—ovarian cancer	0.000295	0.00447	CbGeAlD
Gefitinib—IRAK1—lymph node—ovarian cancer	0.000295	0.00447	CbGeAlD
Gefitinib—MKNK1—lymph node—ovarian cancer	0.000291	0.00441	CbGeAlD
Gefitinib—Erlotinib—CYP1B1—ovarian cancer	0.000289	0.0595	CrCbGaD
Gefitinib—CHEK2—Vincristine—Vinorelbine—ovarian cancer	0.000288	0.0985	CbGdCrCtD
Gefitinib—ORM1—bone marrow—ovarian cancer	0.000281	0.00425	CbGeAlD
Gefitinib—Erlotinib—EGFR—ovarian cancer	0.000273	0.0561	CrCbGaD
Gefitinib—STK10—lymph node—ovarian cancer	0.00024	0.00363	CbGeAlD
Gefitinib—ABCG2—uterine cervix—ovarian cancer	0.000238	0.0036	CbGeAlD
Gefitinib—CHEK2—Vinblastine—Vinorelbine—ovarian cancer	0.000231	0.0792	CbGdCrCtD
Gefitinib—CYP1A1—epithelium—ovarian cancer	0.000228	0.00345	CbGeAlD
Gefitinib—ABCG2—decidua—ovarian cancer	0.000227	0.00343	CbGeAlD
Gefitinib—CYP1A1—uterine cervix—ovarian cancer	0.000226	0.00342	CbGeAlD
Gefitinib—CYP3A5—uterine cervix—ovarian cancer	0.000221	0.00334	CbGeAlD
Gefitinib—ABCG2—endometrium—ovarian cancer	0.000215	0.00326	CbGeAlD
Gefitinib—MAP2K5—lymph node—ovarian cancer	0.000214	0.00325	CbGeAlD
Gefitinib—Vandetanib—VEGFA—ovarian cancer	0.000213	0.0438	CrCbGaD
Gefitinib—ALB—testis—ovarian cancer	0.000211	0.00319	CbGeAlD
Gefitinib—ABCG2—uterus—ovarian cancer	0.000198	0.003	CbGeAlD
Gefitinib—CYP2C19—vagina—ovarian cancer	0.00019	0.00288	CbGeAlD
Gefitinib—CYP1A1—uterus—ovarian cancer	0.000188	0.00285	CbGeAlD
Gefitinib—Vandetanib—EGFR—ovarian cancer	0.00018	0.037	CrCbGaD
Gefitinib—ORM1—lymph node—ovarian cancer	0.000174	0.00264	CbGeAlD
Gefitinib—CYP1A1—female reproductive system—ovarian cancer	0.000169	0.00256	CbGeAlD
Gefitinib—ABCG2—bone marrow—ovarian cancer	0.000168	0.00255	CbGeAlD
Gefitinib—Bosutinib—EGFR—ovarian cancer	0.000168	0.0346	CrCbGaD
Gefitinib—Lapatinib—ABCB1—ovarian cancer	0.000166	0.0341	CrCbGaD
Gefitinib—CYP2C9—female reproductive system—ovarian cancer	0.000163	0.00247	CbGeAlD
Gefitinib—ABCG2—female gonad—ovarian cancer	0.000162	0.00246	CbGeAlD
Gefitinib—ABCG2—vagina—ovarian cancer	0.000161	0.00244	CbGeAlD
Gefitinib—CYP1A1—female gonad—ovarian cancer	0.000154	0.00233	CbGeAlD
Gefitinib—CYP1A1—vagina—ovarian cancer	0.000153	0.00232	CbGeAlD
Gefitinib—ALB—lymph node—ovarian cancer	0.000153	0.00231	CbGeAlD
Gefitinib—ABCB1—myometrium—ovarian cancer	0.000151	0.00228	CbGeAlD
Gefitinib—CYP3A5—female gonad—ovarian cancer	0.000151	0.00228	CbGeAlD
Gefitinib—CYP3A5—vagina—ovarian cancer	0.00015	0.00227	CbGeAlD
Gefitinib—ABCB1—embryo—ovarian cancer	0.000145	0.0022	CbGeAlD
Gefitinib—ABCG2—testis—ovarian cancer	0.000144	0.00218	CbGeAlD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—ovarian cancer	0.00014	0.048	CbGdCrCtD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—ovarian cancer	0.00013	0.0444	CbGdCrCtD
Gefitinib—CYP3A4—female reproductive system—ovarian cancer	0.000124	0.00188	CbGeAlD
Gefitinib—Eye disorder—Paclitaxel—ovarian cancer	0.000124	0.00127	CcSEcCtD
Gefitinib—Cardiac disorder—Paclitaxel—ovarian cancer	0.000123	0.00127	CcSEcCtD
Gefitinib—CYP2D6—female reproductive system—ovarian cancer	0.000122	0.00185	CbGeAlD
Gefitinib—Stomatitis—Docetaxel—ovarian cancer	0.000122	0.00126	CcSEcCtD
Gefitinib—Hepatic failure—Epirubicin—ovarian cancer	0.000122	0.00125	CcSEcCtD
Gefitinib—Decreased appetite—Vinorelbine—ovarian cancer	0.000122	0.00125	CcSEcCtD
Gefitinib—Conjunctivitis—Docetaxel—ovarian cancer	0.000122	0.00125	CcSEcCtD
Gefitinib—Eye pain—Epirubicin—ovarian cancer	0.000121	0.00125	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000121	0.00124	CcSEcCtD
Gefitinib—Fatigue—Vinorelbine—ovarian cancer	0.000121	0.00124	CcSEcCtD
Gefitinib—Hypersensitivity—Topotecan—ovarian cancer	0.000121	0.00124	CcSEcCtD
Gefitinib—Angiopathy—Paclitaxel—ovarian cancer	0.00012	0.00124	CcSEcCtD
Gefitinib—Constipation—Vinorelbine—ovarian cancer	0.00012	0.00123	CcSEcCtD
Gefitinib—Pain—Vinorelbine—ovarian cancer	0.00012	0.00123	CcSEcCtD
Gefitinib—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000119	0.00123	CcSEcCtD
Gefitinib—Arrhythmia—Paclitaxel—ovarian cancer	0.000118	0.00122	CcSEcCtD
Gefitinib—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000118	0.00122	CcSEcCtD
Gefitinib—ABCB1—epithelium—ovarian cancer	0.000118	0.00179	CbGeAlD
Gefitinib—Hypersensitivity—Melphalan—ovarian cancer	0.000118	0.00122	CcSEcCtD
Gefitinib—Epistaxis—Docetaxel—ovarian cancer	0.000118	0.00121	CcSEcCtD
Gefitinib—Asthenia—Topotecan—ovarian cancer	0.000117	0.00121	CcSEcCtD
Gefitinib—Afatinib—ABCB1—ovarian cancer	0.000117	0.0242	CrCbGaD
Gefitinib—ABCB1—uterine cervix—ovarian cancer	0.000117	0.00178	CbGeAlD
Gefitinib—Alopecia—Paclitaxel—ovarian cancer	0.000117	0.00121	CcSEcCtD
Gefitinib—Thrombophlebitis—Doxorubicin—ovarian cancer	0.000117	0.00121	CcSEcCtD
Gefitinib—Vomiting—Chlorambucil—ovarian cancer	0.000117	0.0012	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Epirubicin—ovarian cancer	0.000116	0.00119	CcSEcCtD
Gefitinib—Pruritus—Topotecan—ovarian cancer	0.000116	0.00119	CcSEcCtD
Gefitinib—Malnutrition—Paclitaxel—ovarian cancer	0.000115	0.00119	CcSEcCtD
Gefitinib—Asthenia—Melphalan—ovarian cancer	0.000115	0.00118	CcSEcCtD
Gefitinib—Dermatitis bullous—Epirubicin—ovarian cancer	0.000115	0.00118	CcSEcCtD
Gefitinib—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000114	0.00118	CcSEcCtD
Gefitinib—Pruritus—Melphalan—ovarian cancer	0.000113	0.00117	CcSEcCtD
Gefitinib—Haemoglobin—Docetaxel—ovarian cancer	0.000113	0.00116	CcSEcCtD
Gefitinib—Hepatic failure—Doxorubicin—ovarian cancer	0.000113	0.00116	CcSEcCtD
Gefitinib—Haemorrhage—Docetaxel—ovarian cancer	0.000112	0.00116	CcSEcCtD
Gefitinib—Hepatitis—Docetaxel—ovarian cancer	0.000112	0.00116	CcSEcCtD
Gefitinib—Eye pain—Doxorubicin—ovarian cancer	0.000112	0.00116	CcSEcCtD
Gefitinib—Diarrhoea—Topotecan—ovarian cancer	0.000112	0.00115	CcSEcCtD
Gefitinib—ABCB1—decidua—ovarian cancer	0.000112	0.00169	CbGeAlD
Gefitinib—Urticaria—Vinorelbine—ovarian cancer	0.000111	0.00114	CcSEcCtD
Gefitinib—CYP2D6—female gonad—ovarian cancer	0.000111	0.00168	CbGeAlD
Gefitinib—Urinary tract disorder—Docetaxel—ovarian cancer	0.000111	0.00114	CcSEcCtD
Gefitinib—Body temperature increased—Vinorelbine—ovarian cancer	0.000111	0.00114	CcSEcCtD
Gefitinib—Abdominal pain—Vinorelbine—ovarian cancer	0.000111	0.00114	CcSEcCtD
Gefitinib—Oedema peripheral—Docetaxel—ovarian cancer	0.000111	0.00114	CcSEcCtD
Gefitinib—Urethral disorder—Docetaxel—ovarian cancer	0.00011	0.00113	CcSEcCtD
Gefitinib—Diarrhoea—Melphalan—ovarian cancer	0.00011	0.00113	CcSEcCtD
Gefitinib—Nausea—Chlorambucil—ovarian cancer	0.000109	0.00112	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Doxorubicin—ovarian cancer	0.000107	0.00111	CcSEcCtD
Gefitinib—Anaemia—Paclitaxel—ovarian cancer	0.000107	0.0011	CcSEcCtD
Gefitinib—Erythema multiforme—Docetaxel—ovarian cancer	0.000106	0.00109	CcSEcCtD
Gefitinib—ABCB1—endometrium—ovarian cancer	0.000106	0.00161	CbGeAlD
Gefitinib—Dermatitis bullous—Doxorubicin—ovarian cancer	0.000106	0.00109	CcSEcCtD
Gefitinib—Angioedema—Paclitaxel—ovarian cancer	0.000105	0.00109	CcSEcCtD
Gefitinib—Eye disorder—Docetaxel—ovarian cancer	0.000105	0.00108	CcSEcCtD
Gefitinib—Cardiac disorder—Docetaxel—ovarian cancer	0.000104	0.00107	CcSEcCtD
Gefitinib—ABCG2—lymph node—ovarian cancer	0.000104	0.00158	CbGeAlD
Gefitinib—Vomiting—Topotecan—ovarian cancer	0.000104	0.00107	CcSEcCtD
Gefitinib—Malaise—Paclitaxel—ovarian cancer	0.000104	0.00107	CcSEcCtD
Gefitinib—Rash—Topotecan—ovarian cancer	0.000103	0.00106	CcSEcCtD
Gefitinib—Hypersensitivity—Vinorelbine—ovarian cancer	0.000103	0.00106	CcSEcCtD
Gefitinib—Dermatitis—Topotecan—ovarian cancer	0.000103	0.00106	CcSEcCtD
Gefitinib—Angiopathy—Docetaxel—ovarian cancer	0.000102	0.00105	CcSEcCtD
Gefitinib—Vomiting—Melphalan—ovarian cancer	0.000102	0.00105	CcSEcCtD
Gefitinib—Dehydration—Epirubicin—ovarian cancer	0.000102	0.00105	CcSEcCtD
Gefitinib—Mediastinal disorder—Docetaxel—ovarian cancer	0.000101	0.00104	CcSEcCtD
Gefitinib—Rash—Melphalan—ovarian cancer	0.000101	0.00104	CcSEcCtD
Gefitinib—Dermatitis—Melphalan—ovarian cancer	0.000101	0.00104	CcSEcCtD
Gefitinib—Cough—Paclitaxel—ovarian cancer	0.000101	0.00104	CcSEcCtD
Gefitinib—Asthenia—Vinorelbine—ovarian cancer	0.0001	0.00103	CcSEcCtD
Gefitinib—Dry skin—Epirubicin—ovarian cancer	0.0001	0.00103	CcSEcCtD
Gefitinib—Arrhythmia—Docetaxel—ovarian cancer	0.0001	0.00103	CcSEcCtD
Gefitinib—Hypokalaemia—Epirubicin—ovarian cancer	9.97e-05	0.00103	CcSEcCtD
Gefitinib—Alopecia—Docetaxel—ovarian cancer	9.93e-05	0.00102	CcSEcCtD
Gefitinib—Pruritus—Vinorelbine—ovarian cancer	9.91e-05	0.00102	CcSEcCtD
Gefitinib—CYP1A1—lymph node—ovarian cancer	9.9e-05	0.0015	CbGeAlD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	9.86e-05	0.00102	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	9.86e-05	0.00102	CcSEcCtD
Gefitinib—CYP2D6—testis—ovarian cancer	9.86e-05	0.00149	CbGeAlD
Gefitinib—ABCB1—gonad—ovarian cancer	9.84e-05	0.00149	CbGeAlD
Gefitinib—Malnutrition—Docetaxel—ovarian cancer	9.78e-05	0.00101	CcSEcCtD
Gefitinib—ABCB1—uterus—ovarian cancer	9.78e-05	0.00148	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	9.76e-05	0.001	CcSEcCtD
Gefitinib—Nausea—Topotecan—ovarian cancer	9.72e-05	0.001	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	9.66e-05	0.000994	CcSEcCtD
Gefitinib—Dry mouth—Paclitaxel—ovarian cancer	9.61e-05	0.000989	CcSEcCtD
Gefitinib—Diarrhoea—Vinorelbine—ovarian cancer	9.58e-05	0.000986	CcSEcCtD
Gefitinib—Nausea—Melphalan—ovarian cancer	9.52e-05	0.00098	CcSEcCtD
Gefitinib—Dehydration—Doxorubicin—ovarian cancer	9.43e-05	0.00097	CcSEcCtD
Gefitinib—Infection—Paclitaxel—ovarian cancer	9.36e-05	0.000963	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—ovarian cancer	9.29e-05	0.000956	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—ovarian cancer	9.28e-05	0.000955	CcSEcCtD
Gefitinib—Shock—Paclitaxel—ovarian cancer	9.27e-05	0.000954	CcSEcCtD
Gefitinib—Nervous system disorder—Paclitaxel—ovarian cancer	9.24e-05	0.000951	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—ovarian cancer	9.22e-05	0.000949	CcSEcCtD
Gefitinib—Thrombocytopenia—Paclitaxel—ovarian cancer	9.22e-05	0.000949	CcSEcCtD
Gefitinib—Skin disorder—Paclitaxel—ovarian cancer	9.15e-05	0.000941	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	9.13e-05	0.000939	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	9.13e-05	0.000939	CcSEcCtD
Gefitinib—Anaemia—Docetaxel—ovarian cancer	9.04e-05	0.00093	CcSEcCtD
Gefitinib—Anorexia—Paclitaxel—ovarian cancer	8.98e-05	0.000924	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	8.94e-05	0.00092	CcSEcCtD
Gefitinib—Vomiting—Vinorelbine—ovarian cancer	8.9e-05	0.000916	CcSEcCtD
Gefitinib—Rash—Vinorelbine—ovarian cancer	8.83e-05	0.000909	CcSEcCtD
Gefitinib—Dermatitis—Vinorelbine—ovarian cancer	8.82e-05	0.000908	CcSEcCtD
Gefitinib—Hypotension—Paclitaxel—ovarian cancer	8.8e-05	0.000906	CcSEcCtD
Gefitinib—ABCB1—female reproductive system—ovarian cancer	8.79e-05	0.00133	CbGeAlD
Gefitinib—Pancreatitis—Doxorubicin—ovarian cancer	8.59e-05	0.000884	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—ovarian cancer	8.57e-05	0.000882	CcSEcCtD
Gefitinib—Cough—Docetaxel—ovarian cancer	8.53e-05	0.000878	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—ovarian cancer	8.49e-05	0.000874	CcSEcCtD
Gefitinib—Infestation—Epirubicin—ovarian cancer	8.44e-05	0.000869	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—ovarian cancer	8.44e-05	0.000869	CcSEcCtD
Gefitinib—Dyspnoea—Paclitaxel—ovarian cancer	8.4e-05	0.000864	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	8.37e-05	0.000861	CcSEcCtD
Gefitinib—Nausea—Vinorelbine—ovarian cancer	8.32e-05	0.000856	CcSEcCtD
Gefitinib—ABCB1—bone marrow—ovarian cancer	8.3e-05	0.00126	CbGeAlD
Gefitinib—Erlotinib—ABCB1—ovarian cancer	8.29e-05	0.0171	CrCbGaD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	8.27e-05	0.000851	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—ovarian cancer	8.23e-05	0.000847	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—ovarian cancer	8.21e-05	0.000845	CcSEcCtD
Gefitinib—Decreased appetite—Paclitaxel—ovarian cancer	8.19e-05	0.000843	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—ovarian cancer	8.14e-05	0.000838	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	8.13e-05	0.000837	CcSEcCtD
Gefitinib—Fatigue—Paclitaxel—ovarian cancer	8.12e-05	0.000836	CcSEcCtD
Gefitinib—Constipation—Paclitaxel—ovarian cancer	8.05e-05	0.000829	CcSEcCtD
Gefitinib—Pain—Paclitaxel—ovarian cancer	8.05e-05	0.000829	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—ovarian cancer	8.05e-05	0.000828	CcSEcCtD
Gefitinib—ABCB1—female gonad—ovarian cancer	8e-05	0.00121	CbGeAlD
Gefitinib—Hepatobiliary disease—Epirubicin—ovarian cancer	7.98e-05	0.000822	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—ovarian cancer	7.96e-05	0.00082	CcSEcCtD
Gefitinib—ABCB1—vagina—ovarian cancer	7.95e-05	0.0012	CbGeAlD
Gefitinib—Infection—Docetaxel—ovarian cancer	7.93e-05	0.000816	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—ovarian cancer	7.93e-05	0.000816	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—ovarian cancer	7.86e-05	0.000809	CcSEcCtD
Gefitinib—Shock—Docetaxel—ovarian cancer	7.85e-05	0.000808	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—ovarian cancer	7.83e-05	0.000806	CcSEcCtD
Gefitinib—Thrombocytopenia—Docetaxel—ovarian cancer	7.82e-05	0.000804	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—ovarian cancer	7.81e-05	0.000804	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—ovarian cancer	7.81e-05	0.000804	CcSEcCtD
Gefitinib—Skin disorder—Docetaxel—ovarian cancer	7.75e-05	0.000798	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	7.74e-05	0.000797	CcSEcCtD
Gefitinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	7.7e-05	0.000793	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—ovarian cancer	7.62e-05	0.000784	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—ovarian cancer	7.61e-05	0.000784	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—ovarian cancer	7.61e-05	0.000783	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—ovarian cancer	7.59e-05	0.000781	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—ovarian cancer	7.58e-05	0.00078	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—ovarian cancer	7.58e-05	0.00078	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—ovarian cancer	7.48e-05	0.00077	CcSEcCtD
Gefitinib—Urticaria—Paclitaxel—ovarian cancer	7.48e-05	0.00077	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—ovarian cancer	7.47e-05	0.000768	CcSEcCtD
Gefitinib—Hypotension—Docetaxel—ovarian cancer	7.46e-05	0.000768	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—ovarian cancer	7.45e-05	0.000767	CcSEcCtD
Gefitinib—Abdominal pain—Paclitaxel—ovarian cancer	7.44e-05	0.000766	CcSEcCtD
Gefitinib—Body temperature increased—Paclitaxel—ovarian cancer	7.44e-05	0.000766	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—ovarian cancer	7.43e-05	0.000765	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	7.39e-05	0.00076	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—ovarian cancer	7.37e-05	0.000758	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—ovarian cancer	7.17e-05	0.000737	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—ovarian cancer	7.12e-05	0.000732	CcSEcCtD
Gefitinib—ABCB1—testis—ovarian cancer	7.09e-05	0.00107	CbGeAlD
Gefitinib—Eye disorder—Epirubicin—ovarian cancer	7.08e-05	0.000729	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—ovarian cancer	7.05e-05	0.000725	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—ovarian cancer	7.03e-05	0.000724	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—ovarian cancer	7.01e-05	0.000722	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—ovarian cancer	7.01e-05	0.000722	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—ovarian cancer	6.94e-05	0.000714	CcSEcCtD
Gefitinib—Hypersensitivity—Paclitaxel—ovarian cancer	6.94e-05	0.000714	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—ovarian cancer	6.92e-05	0.000713	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—ovarian cancer	6.91e-05	0.000711	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.89e-05	0.000709	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—ovarian cancer	6.88e-05	0.000708	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—ovarian cancer	6.88e-05	0.000708	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—ovarian cancer	6.87e-05	0.000707	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—ovarian cancer	6.83e-05	0.000703	CcSEcCtD
Gefitinib—Constipation—Docetaxel—ovarian cancer	6.83e-05	0.000703	CcSEcCtD
Gefitinib—Pain—Docetaxel—ovarian cancer	6.83e-05	0.000703	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—ovarian cancer	6.77e-05	0.000697	CcSEcCtD
Gefitinib—Asthenia—Paclitaxel—ovarian cancer	6.76e-05	0.000695	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—ovarian cancer	6.7e-05	0.000689	CcSEcCtD
Gefitinib—Pruritus—Paclitaxel—ovarian cancer	6.66e-05	0.000686	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—ovarian cancer	6.63e-05	0.000682	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—ovarian cancer	6.6e-05	0.000679	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—ovarian cancer	6.55e-05	0.000674	CcSEcCtD
Gefitinib—Gastrointestinal pain—Docetaxel—ovarian cancer	6.53e-05	0.000672	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—ovarian cancer	6.51e-05	0.00067	CcSEcCtD
Gefitinib—Diarrhoea—Paclitaxel—ovarian cancer	6.44e-05	0.000663	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—ovarian cancer	6.36e-05	0.000655	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—ovarian cancer	6.32e-05	0.00065	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—ovarian cancer	6.31e-05	0.000649	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—ovarian cancer	6.31e-05	0.000649	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—ovarian cancer	6.26e-05	0.000645	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—ovarian cancer	6.2e-05	0.000638	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—ovarian cancer	6.1e-05	0.000628	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—ovarian cancer	6.1e-05	0.000628	CcSEcCtD
Gefitinib—Vomiting—Paclitaxel—ovarian cancer	5.99e-05	0.000616	CcSEcCtD
Gefitinib—Malaise—Epirubicin—ovarian cancer	5.95e-05	0.000612	CcSEcCtD
Gefitinib—Rash—Paclitaxel—ovarian cancer	5.94e-05	0.000611	CcSEcCtD
Gefitinib—Dermatitis—Paclitaxel—ovarian cancer	5.93e-05	0.000611	CcSEcCtD
Gefitinib—Hypersensitivity—Docetaxel—ovarian cancer	5.88e-05	0.000605	CcSEcCtD
Gefitinib—Cough—Epirubicin—ovarian cancer	5.76e-05	0.000592	CcSEcCtD
Gefitinib—Asthenia—Docetaxel—ovarian cancer	5.73e-05	0.000589	CcSEcCtD
Gefitinib—Pruritus—Docetaxel—ovarian cancer	5.65e-05	0.000581	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—ovarian cancer	5.64e-05	0.000581	CcSEcCtD
Gefitinib—Nausea—Paclitaxel—ovarian cancer	5.59e-05	0.000576	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.58e-05	0.000574	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—ovarian cancer	5.5e-05	0.000567	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—ovarian cancer	5.49e-05	0.000565	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—ovarian cancer	5.46e-05	0.000562	CcSEcCtD
Gefitinib—Infection—Epirubicin—ovarian cancer	5.35e-05	0.000551	CcSEcCtD
Gefitinib—Cough—Doxorubicin—ovarian cancer	5.33e-05	0.000548	CcSEcCtD
Gefitinib—Shock—Epirubicin—ovarian cancer	5.3e-05	0.000545	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—ovarian cancer	5.28e-05	0.000543	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—ovarian cancer	5.27e-05	0.000543	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—ovarian cancer	5.23e-05	0.000538	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.16e-05	0.000531	CcSEcCtD
Gefitinib—ABCB1—lymph node—ovarian cancer	5.14e-05	0.000779	CbGeAlD
Gefitinib—Anorexia—Epirubicin—ovarian cancer	5.13e-05	0.000528	CcSEcCtD
Gefitinib—Bosutinib—ABCB1—ovarian cancer	5.11e-05	0.0105	CrCbGaD
Gefitinib—Dry mouth—Doxorubicin—ovarian cancer	5.08e-05	0.000523	CcSEcCtD
Gefitinib—Vomiting—Docetaxel—ovarian cancer	5.08e-05	0.000522	CcSEcCtD
Gefitinib—Rash—Docetaxel—ovarian cancer	5.03e-05	0.000518	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—ovarian cancer	5.03e-05	0.000518	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—ovarian cancer	5.03e-05	0.000518	CcSEcCtD
Gefitinib—Infection—Doxorubicin—ovarian cancer	4.95e-05	0.000509	CcSEcCtD
Gefitinib—Shock—Doxorubicin—ovarian cancer	4.9e-05	0.000504	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—ovarian cancer	4.89e-05	0.000503	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—ovarian cancer	4.88e-05	0.000502	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—ovarian cancer	4.84e-05	0.000498	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—ovarian cancer	4.8e-05	0.000494	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—ovarian cancer	4.75e-05	0.000489	CcSEcCtD
Gefitinib—Nausea—Docetaxel—ovarian cancer	4.74e-05	0.000488	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—ovarian cancer	4.68e-05	0.000482	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—ovarian cancer	4.66e-05	0.000479	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.65e-05	0.000478	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—ovarian cancer	4.64e-05	0.000478	CcSEcCtD
Gefitinib—Pain—Epirubicin—ovarian cancer	4.6e-05	0.000474	CcSEcCtD
Gefitinib—Constipation—Epirubicin—ovarian cancer	4.6e-05	0.000474	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—ovarian cancer	4.44e-05	0.000457	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—ovarian cancer	4.4e-05	0.000453	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—ovarian cancer	4.33e-05	0.000446	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.3e-05	0.000443	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—ovarian cancer	4.3e-05	0.000442	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—ovarian cancer	4.28e-05	0.00044	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—ovarian cancer	4.26e-05	0.000438	CcSEcCtD
Gefitinib—Pain—Doxorubicin—ovarian cancer	4.26e-05	0.000438	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—ovarian cancer	4.26e-05	0.000438	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—ovarian cancer	4.26e-05	0.000438	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.07e-05	0.000419	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—ovarian cancer	3.97e-05	0.000408	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—ovarian cancer	3.96e-05	0.000407	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—ovarian cancer	3.94e-05	0.000405	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—ovarian cancer	3.94e-05	0.000405	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—ovarian cancer	3.86e-05	0.000398	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—ovarian cancer	3.81e-05	0.000392	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—ovarian cancer	3.68e-05	0.000379	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—ovarian cancer	3.67e-05	0.000378	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—ovarian cancer	3.57e-05	0.000368	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—ovarian cancer	3.52e-05	0.000363	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—ovarian cancer	3.42e-05	0.000352	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—ovarian cancer	3.41e-05	0.000351	CcSEcCtD
Gefitinib—Rash—Epirubicin—ovarian cancer	3.39e-05	0.000349	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—ovarian cancer	3.39e-05	0.000349	CcSEcCtD
Gefitinib—Nausea—Epirubicin—ovarian cancer	3.2e-05	0.000329	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—ovarian cancer	3.17e-05	0.000326	CcSEcCtD
Gefitinib—Rash—Doxorubicin—ovarian cancer	3.14e-05	0.000323	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—ovarian cancer	3.14e-05	0.000323	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—ovarian cancer	2.96e-05	0.000305	CcSEcCtD
Gefitinib—ABCB1—Metabolism—FASN—ovarian cancer	2.91e-06	2.77e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—ovarian cancer	2.9e-06	2.76e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.9e-06	2.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDKN1B—ovarian cancer	2.89e-06	2.76e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ABCB1—ovarian cancer	2.89e-06	2.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB2—ovarian cancer	2.89e-06	2.75e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—ovarian cancer	2.88e-06	2.75e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—STAT3—ovarian cancer	2.87e-06	2.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—ovarian cancer	2.87e-06	2.73e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PIK3CA—ovarian cancer	2.87e-06	2.73e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL8—ovarian cancer	2.87e-06	2.73e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—ovarian cancer	2.86e-06	2.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—ovarian cancer	2.86e-06	2.72e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SLC5A5—ovarian cancer	2.86e-06	2.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CAV1—ovarian cancer	2.86e-06	2.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MTOR—ovarian cancer	2.85e-06	2.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CB—ovarian cancer	2.85e-06	2.71e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TYMS—ovarian cancer	2.84e-06	2.7e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2—ovarian cancer	2.83e-06	2.7e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.83e-06	2.69e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PIK3CA—ovarian cancer	2.81e-06	2.68e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1B—ovarian cancer	2.8e-06	2.67e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—ovarian cancer	2.8e-06	2.66e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—ovarian cancer	2.77e-06	2.64e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.77e-06	2.64e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STAT3—ovarian cancer	2.77e-06	2.64e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—ovarian cancer	2.76e-06	2.63e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—ovarian cancer	2.76e-06	2.63e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SLC2A1—ovarian cancer	2.76e-06	2.63e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—ovarian cancer	2.76e-06	2.63e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ESR1—ovarian cancer	2.75e-06	2.62e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK3—ovarian cancer	2.74e-06	2.61e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CASP3—ovarian cancer	2.74e-06	2.61e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2—ovarian cancer	2.74e-06	2.61e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—FASN—ovarian cancer	2.74e-06	2.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTNNB1—ovarian cancer	2.73e-06	2.61e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ABCB1—ovarian cancer	2.73e-06	2.6e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—FASN—ovarian cancer	2.71e-06	2.59e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.71e-06	2.58e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6ST—ovarian cancer	2.71e-06	2.58e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.69e-06	2.57e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TYMS—ovarian cancer	2.68e-06	2.55e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPP2R1A—ovarian cancer	2.68e-06	2.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1B—ovarian cancer	2.67e-06	2.55e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.67e-06	2.54e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—ovarian cancer	2.67e-06	2.54e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—ovarian cancer	2.67e-06	2.54e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.67e-06	2.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTEN—ovarian cancer	2.66e-06	2.54e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—ovarian cancer	2.65e-06	2.53e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1B1—ovarian cancer	2.65e-06	2.52e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK3—ovarian cancer	2.64e-06	2.52e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—ovarian cancer	2.64e-06	2.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CTNNB1—ovarian cancer	2.64e-06	2.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—ovarian cancer	2.64e-06	2.51e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—ovarian cancer	2.61e-06	2.49e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK1—ovarian cancer	2.61e-06	2.49e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—ovarian cancer	2.61e-06	2.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CG—ovarian cancer	2.6e-06	2.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APC—ovarian cancer	2.6e-06	2.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—ovarian cancer	2.6e-06	2.48e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—ovarian cancer	2.6e-06	2.48e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.6e-06	2.48e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—ovarian cancer	2.59e-06	2.47e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2.58e-06	2.46e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTEN—ovarian cancer	2.58e-06	2.46e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—ovarian cancer	2.57e-06	2.45e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CD—ovarian cancer	2.55e-06	2.43e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—ovarian cancer	2.55e-06	2.43e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—ovarian cancer	2.54e-06	2.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—ovarian cancer	2.53e-06	2.41e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.52e-06	2.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CTNNB1—ovarian cancer	2.52e-06	2.41e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK1—ovarian cancer	2.52e-06	2.4e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—ovarian cancer	2.52e-06	2.4e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK3—ovarian cancer	2.5e-06	2.38e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.49e-06	2.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK3—ovarian cancer	2.49e-06	2.37e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—ovarian cancer	2.49e-06	2.37e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ABCB1—ovarian cancer	2.49e-06	2.37e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1B1—ovarian cancer	2.47e-06	2.36e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—ovarian cancer	2.47e-06	2.35e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—ovarian cancer	2.46e-06	2.34e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TYMS—ovarian cancer	2.44e-06	2.33e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	2.4e-06	2.29e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.39e-06	2.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—ovarian cancer	2.38e-06	2.27e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK1—ovarian cancer	2.38e-06	2.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—ovarian cancer	2.38e-06	2.27e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—ovarian cancer	2.38e-06	2.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK1—ovarian cancer	2.37e-06	2.26e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPP2R1A—ovarian cancer	2.35e-06	2.24e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—ovarian cancer	2.34e-06	2.23e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—ovarian cancer	2.33e-06	2.22e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—ovarian cancer	2.3e-06	2.2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—ovarian cancer	2.3e-06	2.19e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—ovarian cancer	2.3e-06	2.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CD—ovarian cancer	2.29e-06	2.18e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CAV1—ovarian cancer	2.29e-06	2.18e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK3—ovarian cancer	2.28e-06	2.17e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—ovarian cancer	2.27e-06	2.16e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—ovarian cancer	2.25e-06	2.14e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—ovarian cancer	2.24e-06	2.13e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—ovarian cancer	2.23e-06	2.13e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CB—ovarian cancer	2.23e-06	2.12e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.21e-06	2.11e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK3—ovarian cancer	2.2e-06	2.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—ovarian cancer	2.2e-06	2.1e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—YAP1—ovarian cancer	2.2e-06	2.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—ovarian cancer	2.2e-06	2.09e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—ovarian cancer	2.19e-06	2.09e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.19e-06	2.09e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—ovarian cancer	2.19e-06	2.09e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—ovarian cancer	2.18e-06	2.08e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.18e-06	2.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK1—ovarian cancer	2.17e-06	2.06e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CAV1—ovarian cancer	2.16e-06	2.06e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—ovarian cancer	2.14e-06	2.04e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—ovarian cancer	2.14e-06	2.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—ovarian cancer	2.11e-06	2.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK3—ovarian cancer	2.1e-06	2e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—ovarian cancer	2.1e-06	2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK1—ovarian cancer	2.09e-06	2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—ovarian cancer	2.09e-06	2e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CG—ovarian cancer	2.08e-06	1.98e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—ovarian cancer	2.07e-06	1.97e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.06e-06	1.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—ovarian cancer	2.06e-06	1.96e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.05e-06	1.96e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—ovarian cancer	2.05e-06	1.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—ovarian cancer	2.04e-06	1.95e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.04e-06	1.94e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—ovarian cancer	2.02e-06	1.93e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—ovarian cancer	2.02e-06	1.92e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—ovarian cancer	2.02e-06	1.92e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—ovarian cancer	2.01e-06	1.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK1—ovarian cancer	2e-06	1.91e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—ovarian cancer	2e-06	1.91e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—ovarian cancer	2e-06	1.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CB—ovarian cancer	1.99e-06	1.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MTOR—ovarian cancer	1.99e-06	1.9e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—ovarian cancer	1.98e-06	1.89e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAV1—ovarian cancer	1.97e-06	1.88e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CG—ovarian cancer	1.97e-06	1.87e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—ovarian cancer	1.93e-06	1.84e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—ovarian cancer	1.92e-06	1.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—ovarian cancer	1.92e-06	1.83e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—ovarian cancer	1.91e-06	1.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—ovarian cancer	1.9e-06	1.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—ovarian cancer	1.89e-06	1.8e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.88e-06	1.79e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—ovarian cancer	1.88e-06	1.79e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1B—ovarian cancer	1.87e-06	1.78e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	1.85e-06	1.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—ovarian cancer	1.83e-06	1.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—ovarian cancer	1.83e-06	1.74e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	1.83e-06	1.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—ovarian cancer	1.82e-06	1.74e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—ovarian cancer	1.82e-06	1.73e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CG—ovarian cancer	1.79e-06	1.71e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—FASN—ovarian cancer	1.79e-06	1.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—ovarian cancer	1.79e-06	1.7e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—ovarian cancer	1.78e-06	1.7e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—ovarian cancer	1.77e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAV1—ovarian cancer	1.77e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.76e-06	1.68e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—ovarian cancer	1.76e-06	1.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—ovarian cancer	1.74e-06	1.66e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—ovarian cancer	1.74e-06	1.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—ovarian cancer	1.73e-06	1.65e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CD—ovarian cancer	1.73e-06	1.65e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAV1—ovarian cancer	1.72e-06	1.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—ovarian cancer	1.72e-06	1.64e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.7e-06	1.62e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.69e-06	1.61e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—ovarian cancer	1.69e-06	1.61e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—ovarian cancer	1.68e-06	1.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—ovarian cancer	1.68e-06	1.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—ovarian cancer	1.66e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.63e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAV1—ovarian cancer	1.63e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAV1—ovarian cancer	1.61e-06	1.54e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—ovarian cancer	1.61e-06	1.53e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.61e-06	1.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—ovarian cancer	1.61e-06	1.53e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.6e-06	1.52e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CD—ovarian cancer	1.58e-06	1.5e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.57e-06	1.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—ovarian cancer	1.56e-06	1.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—ovarian cancer	1.54e-06	1.47e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.54e-06	1.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—ovarian cancer	1.54e-06	1.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—ovarian cancer	1.54e-06	1.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—ovarian cancer	1.54e-06	1.46e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CB—ovarian cancer	1.51e-06	1.44e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—ovarian cancer	1.49e-06	1.42e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.48e-06	1.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK3—ovarian cancer	1.47e-06	1.4e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.47e-06	1.4e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.45e-06	1.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—ovarian cancer	1.43e-06	1.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—ovarian cancer	1.42e-06	1.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.41e-06	1.35e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK1—ovarian cancer	1.4e-06	1.33e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.38e-06	1.32e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—ovarian cancer	1.38e-06	1.31e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CB—ovarian cancer	1.37e-06	1.31e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.36e-06	1.29e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.34e-06	1.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—ovarian cancer	1.32e-06	1.26e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.32e-06	1.26e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—ovarian cancer	1.3e-06	1.24e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.3e-06	1.24e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.29e-06	1.23e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.23e-06	1.18e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—ovarian cancer	1.22e-06	1.16e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.2e-06	1.15e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—ovarian cancer	1.19e-06	1.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—ovarian cancer	1.18e-06	1.12e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.13e-06	1.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—ovarian cancer	1.12e-06	1.07e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.12e-06	1.07e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—ovarian cancer	1.11e-06	1.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—ovarian cancer	1.08e-06	1.03e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—ovarian cancer	1.07e-06	1.02e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAV1—ovarian cancer	1.06e-06	1.01e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—ovarian cancer	1.04e-06	9.91e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—ovarian cancer	9.93e-07	9.46e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—ovarian cancer	9.8e-07	9.34e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	9.72e-07	9.27e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—ovarian cancer	9.72e-07	9.26e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	9.68e-07	9.22e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—ovarian cancer	9.19e-07	8.75e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	8.51e-07	8.11e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—ovarian cancer	8.37e-07	7.98e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—ovarian cancer	7.94e-07	7.57e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—ovarian cancer	7.52e-07	7.16e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—ovarian cancer	7.5e-07	7.15e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	7.42e-07	7.07e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	7.34e-07	6.99e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—ovarian cancer	6.91e-07	6.59e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—ovarian cancer	6.85e-07	6.53e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—ovarian cancer	6.84e-07	6.52e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—ovarian cancer	6.41e-07	6.11e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—ovarian cancer	6.14e-07	5.85e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—ovarian cancer	5.99e-07	5.71e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—ovarian cancer	5.65e-07	5.38e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—ovarian cancer	5.6e-07	5.34e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.52e-07	4.31e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—ovarian cancer	3.69e-07	3.52e-06	CbGpPWpGaD
